Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMA-ADJUVO: 177Lu-PSMA as Adjuvant Treatment in High-Risk Prostate Cancer
NCT06449781Phase 2Recruiting
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Jan 2025
- Primary completion
- Nov 2030
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Started Jan 2025; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06449781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06449781.